Ftse Mib
33.834,91
0,00%
DAX
18.325,58
0,77%
S&P 500
5.447,87
-0,31%
NASDAQ
17.496,82
-1,09%
Bitcoin
60.975,41
1,18%
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ NeuroSense Therapeutics Ltd (NRSN) NeuroSense Therapeutics Ltd (NRSN) Notizie

NeuroSense Therapeutics Ltd

NRSN
0,845272
-0,05273 (-5,87%)
25 Giu 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
24/6/202415:00PRNUSNeuroSense Management Provides Corporate Update and First..
21/6/202422:30PRNUSNeuroSense Receives Delisting Notice from Nasdaq and Intends..
20/5/202415:00PRNUSNeuroSense Vice President of R&D Shiran Zimri, Ph.D. to..
14/5/202415:05PRNUSNeuroSense Partners with PhaseV to Optimize Upcoming ALS..
07/5/202414:45PRNUSNeuroSense Announces New Positive Data Analysis from..
02/5/202415:19PRNUSNeuroSense Announces First Quarter 2024 Business Update
22/4/202414:30PRNUSNeuroSense and Genetika+ Initiate Precision Medicine..
18/4/202414:30PRNUSNeuroSense Presents Positive Data Validating Phase 2b..
12/4/202414:30PRNUSNeuroSense to Present PARADIGM Data at the American Academy..
11/4/202401:16PRNUSNeuroSense Announces Pricing of $4.5 Million Registered..
09/4/202414:30PRNUSNeuroSense Collaborates with Lonza to Identify Exosome-based..
05/4/202415:29PRNUSNeuroSense Announces Year End 2023 Financial Results and..
22/2/202414:25EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/2/202414:30PRNUSNeuroSense Reports Additional Positive Results from its ALS..
13/2/202419:20EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13/2/202416:14EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
07/2/202415:38EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/2/202415:27PRNUSNeuroSense Regains Compliance with NASDAQ Minimum Bid Price..
09/1/202414:49EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/1/202414:48EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/1/202414:45PRNUSNeuroSense Recaps Positive 2023 Achievements Including..
27/12/202323:03EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
27/12/202323:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
27/12/202323:00PRNUSNeuroSense Announces Receipt of Nasdaq Notice Regarding..
21/12/202314:45EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/12/202322:30EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
14/12/202315:41EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/12/202315:24PRNUSNeuroSense Reports New Data: Statistically Significant..
05/12/202321:15EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
05/12/202321:00EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
05/12/202314:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/12/202314:00PRNUSNeuroSense's Phase 2b ALS Trial Achieves Primary Safety and..
05/12/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
04/12/202322:01PRNUSNeuroSense to Report Phase 2b ALS Topline Primary Safety and..
04/12/202312:17EDGAR2Form POS AM - Post-Effective amendments for registration..
28/11/202315:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28/11/202314:45PRNUSNeuroSense Announces Third Quarter 2023 Financial Results..
21/11/202316:36EDGAR2Form POS AM - Post-Effective amendments for registration..
13/11/202315:28EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13/11/202315:20PRNUSNeuroSense Receives U.S. FDA Confirmation of CMC Strategy..
09/11/202315:00PRNUSNeuroSense Therapeutics to Present at Upcoming U.S. and..
06/11/202314:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/11/202314:30PRNUSNeuroSense Completes Dosing of Last Patient in the..
01/11/202314:00PRNUSNeuroSense Therapeutics to Participate in BIO-Europe Fall
17/10/202314:45EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
17/10/202314:30PRNUSNeuroSense CEO Provides Q3 2023 Update
04/10/202315:12EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/10/202315:10PRNUSNeuroSense's PrimeC Demonstrates Outstanding Effect on ALS..
02/10/202317:39EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/9/202315:16EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
Apertura: 0,841 Min: 0,80 Max: 0,89
Chiusura: 0,898

La tua Cronologia

NASDAQ
NRSN
NeuroSense Therapeutics
COIN
BARETH
TSXV
GAIA
Gaia Grow
USOTC
CLPBF
Coloplast AS (PK)
BIT
P1ZTV4
NLBNPIT1ZTV4 20240621 48
COIN
EPXEUR
Ellipsis X
USOTC
DOOSF
Doosan Fuel Cell (PK)
LSE
SUMM
Summit Therapeutics
LSE
70SN
Inter-am. 7.50%
USOTC
CTSDF
Converge Technology Solu... (QX)
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network